featured
news articles

Total number of categories

Total number of articles

Market/Novel Tech

Applied Genetic Technologies Corporation (ACGT Inc.) have terminated a gene therapy study for X-linked retinoschisis

Applied Genetic Technologies Corporation (NASDAQ: AGTC), a gene therapy company, indicated that a treatment of a X-linked retinoschisis (XLRS) disorder has confirmed that interim six-month data from a Phase I/II clinical trial (rAAV2tYF-CB-hRS1) have no signs of clinical activity at six-months.  AGTC announced that the company will not further develop the XLRS gene product.   […]

Read full story
Featured

CRISPR gene editing technology may initiate LCA clinical research study for Phase I/II

Clinical research for gene editing technology will be aiming to start a Phase I/II interventional trial to treat Leber congenital amaurosis type 10 (LCA10).  LCA10 is the most common form of a retinal degenerative monogenic disorder caused by mutations in a gene of the centrosomal protein (290kD).  The clinical study plan aims to enrol between […]

Read full story
Research

Strabismus indicates that Leonardo da Vinci may have some evidence among works of sculpture and painting

A UK researcher has identified that evidence may suggest Leonardo da Vinci had intermittent exotropia, which may result in an ability to switch to monocular vision seen in some of his works of art.  The researcher explained that da Vinci had an ability to draw or paint great artistic works, literally in the “eye”.  The […]

Read full story
Introduction

January 16th, 2019: “EURETINA-Brief”© Issue No. 185

by Dr. Gearóid Tuohy   Dear EURETINA Members,   A very warm welcome to the January 16th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”.  EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is […]

Read full story
Market/Novel Tech

Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10

Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the exercise of an Allergan option to develop and commercialize “EDIT-101” – a CRISPR-based technology for the treatment of Leber Congenital Amaurosis type 10 (LCA10).  CRISPR (an acronym for “clustered regularly […]

Read full story
Featured

***EURETINA / Fight for Sight launch Sub-Macular Haemorrhage (SMH) Clinical Research Call***

EURETINA, through a collaboration with Fight for Sight, have announced a dedicated Research Call to support clinical research in the field of sub-macular haemorrhage (SMH), valued at up to €2 million.  The Research Call seeks proposals from suitably qualified clinical investigators to address the current clinical uncertainty in respect of the medical management of sub-macular […]

Read full story

Latest News

Book Review